OKUR on Nasdaq

OnKure Therapeutics, Inc.

American pharmaceutical preparations company based in Boulder. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerOKUR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoulder, Colorado1
  • Incorporated inDE2
  • Business address6707 Winchester Circle, Suite 400, Boulder, Co 803012
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases. By selectively sparing the wild-type enzyme and preferentially targeting the mutated form of the protein, which is oncogenic and drives disease processes in both cancer and vascular overgrowth syndromes, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that …3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-50.7%Return on equity4
-$51.2MFree cash flow4

Financial statements

Operating income67854-$54.4M in 2024+178% since 2020
-$60.0M-$40.0M-$20.0M02020: -$19.6M-$19.6M20202021: -$39.8M-$39.8M2021+104%2022: -$53.8M-$53.8M2022+35%2023: -$36.9M-$36.9M2023−31%2024: -$54.4M-$54.4M2024+47%
Net income67854-$52.7M in 2024+171% since 2020
-$60.0M-$40.0M-$20.0M02020: -$19.5M-$19.5M20202021: -$39.8M-$39.8M2021+104%2022: -$52.0M-$52.0M2022+31%2023: -$35.3M-$35.3M2023−32%2024: -$52.7M-$52.7M2024+49%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Research and development$48.3M$43.8M
General and administrative$14.7M$10.6M
Total operating expenses$63.0M$54.4M
Loss from operations-$63.0M-$54.4M
Interest income$3.4M$2.0M
Interest and other expense-$8.0K-$300.0K
Total other income (expense)$3.4M$1.7M
Net loss and comprehensive loss-$59.5M-$52.7M
Net loss per share attributable to common stockholders: Basic-$4.40-$15.28
Net loss per share attributable to common stockholders: diluted-$4.40-$15.28
Weighted average shares outstanding: Basic13.5M shares3.4M shares
Weighted average shares outstanding: diluted13.5M shares3.4M shares

Compare OnKure Therapeutics, Inc. with another company

Leadership

Who has led OnKure Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gregory J. Flesher2021–2022
  2. Nicholas A. Saccomano2024–now

Chair

  1. Michael G. Grey2021–2023

President

  1. Gregory J. Flesher2021–2022
  2. Nicholas A. Saccomano2024–now

Chief financial officer

  1. Vineet R. Jindal2021
  2. Jason A. Leverone2024–now

Chief operating officer

  1. Michael Cruse2022
2025
Board members and other officers (24)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorR. Michael Carruthers named Oct 21, 202440

Former names

  • Reneo Pharmaceuticals, Inc.Jan 8, 2018 to Oct 2, 20242

Timeline

  1. Oct 8, 2024New chief executive Nicholas A. Saccomano becomes CEO12
  2. Apr 8, 2021New chief executive Gregory J. Flesher becomes CEO13

Filings

330 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 49 major events, 127 insider forms, 58 large holders, 1 private raises, 74 other. The latest 20:

  1. Oct 7, 2026SCHEDULE 13G EDGAR
  2. Sep 23, 20264 EDGAR
  3. Sep 23, 20264 EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 20264/A EDGAR
  8. Aug 13, 20268-K EDGAR
  9. Aug 11, 20264 EDGAR
  10. Aug 11, 20264 EDGAR
  11. Aug 11, 20264 EDGAR
  12. Aug 11, 20264 EDGAR
  13. Aug 11, 20264 EDGAR
  14. Aug 11, 20264 EDGAR
  15. Aug 11, 20264 EDGAR
  16. Aug 11, 20264 EDGAR
  17. Aug 11, 20264 EDGAR
  18. Aug 11, 20264 EDGAR
  19. Aug 11, 20264 EDGAR
  20. Aug 10, 2026SCHEDULE 13G/A EDGAR

The 330 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

36 open-market trades by officers, directors and large owners since October 2021: 16 buys and 20 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 21, 2026Leverone Jason A.Chief Financial OfficerSale302$2.97$897Form 4
Sep 21, 2026Saccomano Nicholas APresident and CEOSale87$2.97$258Form 4
Jun 22, 2026Leverone Jason A.Chief Financial OfficerSale303$4.40$1.3KForm 4
Jun 22, 2026Saccomano Nicholas APresident and CEOSale86$4.40$378Form 4
Mar 23, 2026Leverone Jason A.Chief Financial OfficerSale301$4.16$1.3KForm 4
Mar 23, 2026Saccomano Nicholas APresident and CEOSale86$4.16$358Form 4
Dec 22, 2025Leverone Jason A.Chief Financial OfficerSale302$2.97$897Form 4
Dec 22, 2025Saccomano Nicholas APresident and CEOSale87$2.97$258Form 4
Sep 22, 2025Leverone Jason A.Chief Financial OfficerSale303$2.62$794Form 4
Sep 22, 2025Saccomano Nicholas APresident and CEOSale88$2.62$231Form 4
Jun 23, 2025Saccomano Nicholas APresident and CEOSale88$2.38$209Form 4
Jun 23, 2025Leverone Jason A.Chief Financial OfficerSale303$2.38$721Form 4
May 15, 2025ACORN CAPITAL ADVISORS GP, LLC10% ownerBuy1,400,000$1.85$2.6MForm 4
May 15, 2025Cormorant Private Healthcare Fund III LPSale1,813,439$1.85$3.4MForm 4
May 12, 2025Cormorant Global Healthcare Master Fund, LPSale24,300$1.99$48.4KForm 4
Apr 7, 2025Saccomano Nicholas APresident and CEOSale516$2.67$1.4KForm 4
Apr 7, 2025Leverone Jason A.Chief Financial OfficerSale1,844$2.67$4.9KForm 4
Apr 4, 2025Saccomano Nicholas APresident and CEOSale358$3.33$1.2KForm 4
Apr 4, 2025Leverone Jason A.Chief Financial OfficerSale1,278$3.33$4.3KForm 4
Sep 25, 2024Leonard Braden MichaelBuy68,746$1.50$103.1KForm 4

All 36 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 4, 2024Raised $65 million in a private offering of equity Form D: 20 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 75. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.3,998,333$18.2M0.2%No change
Bvf Inc/il3,235,778$14.8M0.4%+1,256,806
Acorn Capital Advisors, LLC2,839,674$12.9M3.5%No change
StepStone Group LP2,660,612$12.1M0.6%No change
ADAR1 Capital Management, LLC2,238,684$10.2M0.5%−196,257
Vivo Capital, LLC1,927,710$8.8M0.8%No change
Vestal Point Capital, LP1,825,699$8.3M0.2%−14,120
BlackRock, Inc.1,499,845$6.8M0.0%+1,450,258
Trails Edge Capital Partners, LP1,438,456$6.6M1.0%New
Vanguard Capital Management LLC1,437,039$6.6M0.0%+854,562
Adage Capital Partners Gp, L.l.c.1,204,819$5.5M0.0%No change
Citadel Advisors LLC1,187,047$5.4M0.0%+1,149,460
Sio Capital Management, LLC1,078,965$4.9M0.8%No change
Prosight Management, LP978,992$4.5M0.8%−1,175,389
Logos Global Management LP963,855$4.4M0.2%New
Geode Capital Management, LLC724,438$3.3M0.0%+625,688
NEA Management Company, LLC478,548$2.2M0.1%No change
State Street Corp463,662$2.1M0.0%+450,200
Ensign Peak Advisors, Inc431,631$2.0M0.0%New
Renaissance Technologies LLC358,738$1.6M0.0%−18,512
Sofinnova Investments, Inc.321,692$1.5M0.1%+179,992
Carlyle Group Inc.269,895$1.2M0.0%No change
Affinity Asset Advisors, LLC240,963$1.1M0.1%No change
Dv Equities, LLC240,963$1.1M0.2%New
Seven Fleet Capital Management LP240,963$1.1M0.2%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66